



Reg. Office: 28, Level 1, am @ 10, MB Towers, H No. 8-2-624/A/1, Road No. 10, Banjara Hills, Hyderabad – 500034, Telangana
Corp Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai – 400053
Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com
CIN: L33100TG1991PLC013266 | **Tel:** +91 9167469649

August 14, 2018

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held today, inter alia, considered and approved the following:

1. Resignation of M/s Prakash Modi & Associates, Chartered accountants, with immediate effect, due to their inability to continue as statutory auditor of the company due to pre-occupation.
2. Appointment of M/s Dinesh H Agarwal & Company, Chartered Accountants, as new statutory auditor to fill the casual vacancy caused by said resignation, subject to approval of member in the ensuing annual general meeting for period of 3 years from FY 2018-2019 till FY 2020-2021.
3. Unaudited Financial Results for the quarter ended June 30, 2018 along with Limited Review Report thereon.
4. Confirmation of Directors appointed during the year.
5. Book Closure dates from September 26, 2018 till September 28, 2018 for the purpose of Annual General Meeting.



Reg. Office: 28, Level 1, am @ 10, MB Towers, H No. 8-2-624/A/1, Road No. 10, Banjara Hills, Hyderabad – 500034, Telangana
Corp Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai – 400053
Email ID: rubraltd@gmail.com | Website: www.rubramed.com
CIN: L33100TG1991PLC013266 | Tel: +91 9167469649

6. Notice of 27th Annual General Meeting scheduled to be held on September 29, 2018.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**

A handwritten signature in blue ink, appearing to read "Abha Kapoor", with a horizontal line underneath.

Abha Kapoor
Director (Finance) and Chief Financial Officer
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the Quarter and Year ended June 30, 2018

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for previous period ended
		June 30, 2018	March 31, 2018	June 30, 2017	March 31, 2018
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	9.09	34.08	92.30	229.80
II	Other Income	0.00	0.00	6.70	15.98
III	Total Income (I + II)	9.09	34.08	99.00	245.78
IV	Expenses:				
	Cost of Materials Consumed	0.00	0.17	0.00	101.70
	Purchases of Stock in Trade	9.00	0.00	86.94	86.94
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	1.38	4.50	0.32	12.96
	Finance Costs	0.01	0.00	0.00	0.00
	Depreciation & amortisation expense	0.01	0.01	0.01	0.04
	Other Expenses	0.74	15.92	6.66	31.69
	Total Expenses (IV)	11.14	20.60	93.93	233.33
V	Profit / (loss) before exceptional items and tax (III-IV)	-2.05	13.48	5.07	12.45
VI	Exceptional Items	0.00	-28.82	0.00	-28.82
VII	Profit / (loss) before tax (V-VI)	-2.05	-15.34	5.07	-16.37
VIII	Tax Expense:				
	(1) Current tax	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-2.05	-15.34	5.07	-16.37
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-2.05	-15.34	5.07	-16.37
XIV	Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-2.05	-15.34	5.07	-16.37
XVI	Earnings per equity share (for continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.09 0.09	0.00 0.00
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.09 0.09	0.00 0.00
1	NOTES:				
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.				
3	The Segment - wise details are not applicable to the Company as the Company has no segments.				
4	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.				
4	Previous period's figures have been reclassified / regrouped, wherever necessary.				

For Rubra Medicaments Limited



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Place: Mumbai
Date:- August 14, 2018



DINESH H AGARWAL & CO

CHARTERED ACCOUNTANTS

Limited Review Report of the Auditors

To,
The Board of Directors
Rubra Medicaments Ltd
Mumbai

Sub: Limited Review Report

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Ltd for the period ended June 30, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dinesh H Agarwal & Company
Chartered Accountants
Firm Registration No: FRN 129273W

CA Dinesh Agarwal
Partner
Membership No: 045393



Date: August 14, 2018

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com